Seven Eight Capital LP Purchases 5,898 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Seven Eight Capital LP lifted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 64.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,052 shares of the medical device company’s stock after buying an additional 5,898 shares during the quarter. Seven Eight Capital LP’s holdings in Cooper Companies were worth $1,314,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in Cooper Companies by 303.0% in the 1st quarter. Vanguard Group Inc. now owns 23,099,975 shares of the medical device company’s stock worth $2,343,723,000 after buying an additional 17,367,502 shares during the period. Capital World Investors increased its position in Cooper Companies by 301.7% during the first quarter. Capital World Investors now owns 5,654,023 shares of the medical device company’s stock worth $573,657,000 after acquiring an additional 4,246,519 shares during the period. Janus Henderson Group PLC raised its stake in Cooper Companies by 279.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,437,064 shares of the medical device company’s stock valued at $348,723,000 after purchasing an additional 2,532,186 shares during the last quarter. Impax Asset Management Group plc boosted its holdings in Cooper Companies by 31.0% in the 2nd quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company’s stock valued at $205,511,000 after purchasing an additional 558,886 shares during the period. Finally, Bessemer Group Inc. grew its position in Cooper Companies by 305.2% in the 1st quarter. Bessemer Group Inc. now owns 2,000,910 shares of the medical device company’s stock worth $203,013,000 after purchasing an additional 1,507,049 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Morgan Stanley raised their price objective on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 10th. Piper Sandler boosted their price objective on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Robert W. Baird raised their target price on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Finally, Wells Fargo & Company boosted their price target on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $115.00.

Insider Buying and Selling at Cooper Companies

In other news, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares in the company, valued at $520,488.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Agostino Ricupati sold 1,601 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Daniel G. Mcbride sold 114,992 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 141,381 shares of company stock worth $14,927,361. 2.00% of the stock is currently owned by insiders.

Cooper Companies Stock Up 0.5 %

COO opened at $111.10 on Friday. The Cooper Companies, Inc. has a twelve month low of $75.93 and a twelve month high of $112.38. The firm has a market cap of $22.12 billion, a price-to-earnings ratio of 65.35, a PEG ratio of 2.60 and a beta of 0.98. The firm’s 50-day simple moving average is $97.09 and its 200-day simple moving average is $95.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.84 earnings per share. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.66 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.